The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Covidien

  • COV
  • NYSE
  • Consumer Products
  • Latest 86.83
  • Currency US$
  • Change 0.13
  • Percent Change 0.15 %
  • Volume 2,547,151
  • Fri Aug 29, 2014 04:00 PM EDT NYSE data delayed 15 minutes.
  • Open 87.05
  • Previous Close 86.83
  • High 87.05
  • Low 86.47
  • Bidx0 71.68
  • Askx0 92.00
  • 52-week High06/16 92.68
  • 52-week Low09/03 59.17
  • Beta 1.169
  • Market Cap 39,149.91M
  • EPS 3.91
  • P/E 22.207
  • Forward P/E 19.69
  • PEG 2.19
  • Annual Dividend 1.28
  • Yield 1.474

News

Financials & Calendars

Income Statement

  • Sales $10,375,000,000
  • Earnings $1,607,000,000
  • Return on Equity 16.95%

Cash Flow

  • Cash Flow --
  • Cash $1,178,000,000
  • Current Ratio 2.04

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $20,507,000,000
  • Liabilities $10,945,000,000
  • Liabilities-to-Equity Ratio 1.14

Price Ratios

  • Price to Sales 3.77
  • Price to Book 4.09
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 25 $1.00 Nov 14 $1.01
Surprises Jul 25 4.00% n/a n/a
Dividends Jul 25 $0.32 n/a n/a
Splits n/a -- n/a n/a

12 months ended Sep 01, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Covidien PLC, formerly Covidien Ltd, is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its business through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical, soft tissue repair, energy, oximetry and monitoring, airway and ventilation, vascular, SharpSafety and clinical care products; Imaging Solutions, which includes the development, manufacture and marketing of radiopharmaceuticals and contrast products; Pharmaceutical Products, which includes the development, manufacture and distribution of dosage pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, which includes the development, manufacture and sale of nursing care products, medical surgical products and original equipment manufacturer products.

Related Securities
Symbol Type Latest % Chg

Officers

  • Jose E. Almeida Chairman;President and C.E.O
  • Charles J. Dockendorff C.F.O. and Exec. V.P.
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

20 ON HATCH LOWER HATCH STREET
DUBLIN, L2
DUBLIN

Phone: (353)-1438-1700

cole.lannum@covidien.com
www.covidien.com

Ideas & Discussion

Live Discussion of COV on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.